PARP Inhibitors Differentially Regulate Immune Responses in Distinct Genetic Backgrounds of High-Grade Serous Tubo-Ovarian Carcinoma.

ABSTRACT:

Abstract

Immune checkpoint inhibitors (ICI) have revolutionized treatment for several tumor indications without demonstrated benefit for patients with ovarian cancer. To improve the therapeutic ratio of ICIs in patients with ovarian cancer, several different clinical trials are testing combinations with poly(ADP-ribose) polymerase (PARP) inhibitors. Comparing the immunomodulatory effects of clinically advanced PARP inhibitors (PARPi) may help to identify the best partner to combine with ICIs. We examined the treatment effect of talazoparib (a PARP trapper) and veliparib (a solely PARP enzymatic inhibitor) in homologous recombination deficient (HRD) and homologous recombination proficient high-grade serous tubo-ovarian carcinoma (HGSC) cell lines on immune-related gene expression. W

SUBMITTER: Doro Pereira L 

PROVIDER: S-EPMC11836641 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature